Q2 2026
EPS
$3.02
est $2.73+10.7%
Revenue
$1.00B
est $977M+2.8%
Biotech R&D budgets are unfreezing: the Discovery and Safety Assessment segment booked its highest net book-to-bill in nearly four years, with demand improving across both large pharma and small-cap biotech clients. That was enough to lift full-year non-GAAP EPS guidance to $11.15 to $11.45 and push organic growth guidance back to positive territory, with management's read on the order book due on today's 9:00 AM ET call.
Loading…
